MedPath

Exploring a Patient-centered Approach to Mifepristone Administration in Medical Abortion

Not Applicable
Completed
Conditions
Termination of Pregnancy
Interventions
Registration Number
NCT01811056
Lead Sponsor
Gynuity Health Projects
Brief Summary

This study will test ways to give women more options and flexibility when they are ending their unwanted pregnancies. The investigators will look at uptake and acceptability of using mifepristone outside of the clinic for pregnancy termination.

Detailed Description

This study will investigate the uptake of mifepristone administration outside of the health center for pregnancy termination and its acceptability to women and to their providers. In addition, we plan to evaluate rates of follow-up, adherence, efficacy, complications, days of missed work and/or school, and lost income. This will be a prospective, comparative, non-randomized, open-label study. All women who are seeking medical abortion will be offered participation in the study. Women who enroll in the study will be given a choice between taking the mifepristone outside the center or in the center setting.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
401
Inclusion Criteria
  • Women 18 years and older
  • seeking medical abortion services
  • in general good health
  • assessed by a clinician to have an intrauterine pregnancy less than 64 days L.M.P on the day mifepristone will be taken
  • eligible for medical abortion according to clinician and center standards.
Exclusion Criteria
  • will be followed up by beta HCG and not ultrasound

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Out-of-Center Use of MifepristoneMifepristoneParticipants who choose to take the mifepristone outside of the center
Primary Outcome Measures
NameTimeMethod
Proportion of participants who would recommend outside-of-center administration to a friend1-2 weeks
Proportion of participants who would choose outside of center administration of mifepristone again1-2 weeks
Secondary Outcome Measures
NameTimeMethod
Proportion of women who select outside-of-clinic use of mifepristone1-2 weeks
Adherence1-2 weeks

Did not take complete therapy Mifepristone not taken at scheduled time Mifepristone not taken within 63 days L.M.P. Misoprostol not taken within 48 hours of mifepristone administration Did not return for confirmation of outcome

Success Rates/Method Failure1-2 weeks

Ongoing pregnancy at study end Incomplete abortion at study end Medically indicated surgical intervention during study

Provider-related outcomes1-2 weeks

Unscheduled visits to center Unscheduled calls to center/clinician on-call Provider satisfaction- better than center mifepristone, equivalent, or worse; impact on workload; impact on quality of care

Trial Locations

Locations (3)

Planned Parenthood of the Great Northwest

🇺🇸

Seattle, Washington, United States

Planned Parenthood of New York City

🇺🇸

New York, New York, United States

Planned Parenthood of Northern New England

🇺🇸

Barre, Burlington, Rutland, Vermont, United States

© Copyright 2025. All Rights Reserved by MedPath